NeoGenomics Enhances Oncology Testing with Epic Aura Integration for Better Patient Outcomes
- NeoGenomics improves oncology testing by integrating with the Epic Aura platform.
- This advancement enables more efficient test ordering for healthcare providers.
- The integration aims to enhance patient outcomes in cancer care.
Earlier this week, NeoGenomics, Inc. announced a significant advancement in its oncology testing capabilities by integrating its portfolio into the Epic Aura platform.
Advancing Oncology Testing through Innovative Integration
This integration facilitates oncologists and health systems across the United States to efficiently order tests for solid tumors and hematologic malignancies. Moreover, it provides healthcare professionals with direct access to results through the Epic electronic health record system. By adopting a 'build once, deploy broadly' model, NeoGenomics significantly lowers the adoption barriers that hospitals typically face when integrating new testing solutions.
This strategic decision is not just a technological upgrade; it aims to streamline the test ordering process. This simplification is likely to promote the wider utilization of NeoGenomics' testing solutions. As the company prepares to introduce future offerings, including liquid biopsy and molecular residual detection, the integration into Epic Aura positions NeoGenomics to meet upcoming market demands more effectively.
Enhancing Patient Outcomes Through Increased Access
This integration is expected to improve accessibility for healthcare providers, thereby enhancing patient outcomes. By seamlessly incorporating advanced diagnostic capabilities into existing healthcare infrastructures, NeoGenomics aims to ensure that oncologists can make informed decisions more quickly and efficiently.
Future Prospects in Diagnostic Technology
The move reflects NeoGenomics' commitment to innovation in the oncology testing landscape. By positioning its services within the widely used Epic Aura platform, NeoGenomics not only streamlines the operational aspects but also strengthens its competitive edge, paving the way for new advancements in oncology diagnostics.
As NeoGenomics continues to enhance its testing capabilities, the integration with Epic may serve as a blueprint for future innovations, underscoring a dedicated effort to improve cancer care through technology.